Compare Travere Therapeutics Inc. Common Stock (TVTX) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs ProShares Ultra Gold ETF — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while ProShares Ultra Gold ETF trades at $45.27 (market cap $730.54M). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 6.7× ProShares Ultra Gold ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and ProShares Ultra Gold ETF for 25 Days on average.
| TVTX | UGL | |
|---|---|---|
Market Cap | $4.88B | $730.54M |
Volume | 1,668,577 | 1,700,224 |
Sector | Health | Leveraged / Inverse |
52-Week High | $67.52 | $85.62 |
52-Week Low | $26.79 | $42.79 |
Typical Hold Time | 0 Days | 25 Days |
Enterprise Value | $5.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
UGL is trading at $45.70, down 0.39% on the day, with a bearish technical signal driven by moving averages and key indicators like ADX. Financial ratios are unavailable, limiting fundamental assessment. Recent news highlights gold price volatility amid shifting Fed rate expectations and Treasury yield pressures, influencing sentiment.
The outlook remains cautious due to technical weakness and macroeconomic headwinds. Risks include persistent rate-hike uncertainty and gold market sensitivity. Investment potential hinges on future financial disclosures and gold price stabilization, but current data gaps and bearish signals suggest limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
